The Ebola virus is one of the world's deadliest. It creates an especially aggressive form of hemorrhagic fever which, in the worst cases, will send a patient into shock before death, after bleeding internally and externally.

But an Owensboro company may have an answer.

Kentucky BioProcessing extracts a substance from genetically engineered tobacco plants to make what's called a "humanized" version of Ebola antibodies. These antibodies are combined to make a treatment cocktail called MB-003.

Monkeys, which can be infected with the Ebola virus just like humans, were tested with MB-003 at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). They were treated with MB-003 for five days following the infection's onset. In 43% of the tests, the monkeys survived.

The Owensboro facility can produce MB-003 quickly and cheaply so that needs may be met more expeditiously, according to Kentucky BioProcessing COO Barry Bratcher.

The World Health Organization has kept track of outbreaks of Ebola--which first appeared in 1976--including separate recent ones in the Congo.